International Journal of Core Engineering & Management
Volume-7, Issue-10, 2024 ISSN No: 2348-9510

ADVANTAGES AND LIMITATIONS OF CLOUD ENVIRONMENTS IN BIOPHARMACEUTICAL MANUFACTURING – LITERATURE REVIEW

Ravi Kiran Koppichetti
koppichettiravikiran@gmail.com

Abstract

Biopharmaceuticals are vital in healthcare, playing a crucial role in researching, developing, and producing new biotechnological drugs and therapies to prevent, diagnose, and treat diseases. Enhancing their manufacturing process to be faster, more consistent, less expensive, and more productive is not just important; it's a necessity. Adopting cloud technology can help manufacturing companies streamline processes and reduce production costs. This review paper provides insights into cloud technology in biopharmaceutical manufacturing, outlining its benefits and limitations. It aims to assist IT professionals and business leaders in developing effective strategies while guiding cloud service providers in creating tailored solutions for the biopharmaceutical sector.

Keywords: Cloud computing, Biopharmaceutical industry, Data integrity, Data security, Cloud implementation, Manufacturing

I. INTRODUCTION

In 2003, a Wall Street Journal article criticized the biopharmaceutical industry for lagging behind potato chip and soap manufacturers in its manufacturing techniques [1]. Since then, the industry has improved some processes by adopting quality-by-design practices, implementing new monitoring technologies, and leveraging scientific advancements. Nevertheless, there is still a need for enhanced manufacturing technology, equipment, and quality practices, which can be costly.

The technology gap in the biopharmaceutical industry is mainly due to a conservative approach to process improvement influenced by uncertain regulatory requirements. In 2004, the U.S. Food and Drug Administration (FDA) issued two critical guidelines to improve understanding of quality assurance [2] and encourage the use of advanced monitoring technologies in manufacturing [3].

Cloud technology has emerged, creating a gap due to its accelerated adoption in other manufacturing sectors. The FDA has encouraged biopharmaceutical companies to use this new technology. Still, the companies are having difficulty adopting it because of the complexities involved in its deployment and significantly high upfront investment. This paper focuses on the

advantages and limitations of cloud environments in Biopharmaceutical manufacturing industries and how companies and cloud service providers can overcome the challenges.

II. BACKGROUND

Data integrity refers to data's accuracy, consistency, and completeness throughout its lifecycle. It guarantees that we keep information accurate and dependable from the moment we create it until we access or use it. Data integrity ensures that data is not corrupted or tampered with in any unauthorized manner. Protection

Data protection in the cloud and information safety are vital for all companies. However, these issues can be life and death in the life sciences sector. Any alterations to datasets could lead to life-threatening consequences for patients, which makes it essential to maintain data integrity in cloud computing. The research objective was to bridge the gap between industry standards and the ALCOA+ Data Integrity model, aligning it with cloud computing technology. This alignment protects life-critical data stored in the cloud [4].

The FDA mandated strict compliance with written production and process control procedures. The mandate ensured they correctly accounted for all equipment used in the production process and confirmed its identity, strength, quality, and purity [4]. A crucial aspect of the validation process was the transfer of responsibility for the hardware from the manufacturing company to the cloud Service Provider, which required full approval from the FDA [5].

III. ADVANTAGES OF CLOUD COMPUTING

A. **Scalability and Performance:** Cloud computing provides near-limitless processing and storage capacity, which is essential for Biopharmaceutical manufacturing companies [6]. The process engineers and data scientists who work on the data sets available from the manufacturing units can use the high processing capacity to develop and run their models. Storing all the manufacturing process data in the cloud can lead to easy retrieval and analysis. It helps better manage failures, data analysis, and computational jobs.

B. **Better Connectivity**: The Biopharmaceutical manufacturing process contains multiple computerized equipment in the cultivation, purification, formulation, quality control, media, and buffer formulation stages [10]. Cloud computing offers better and more efficient connectivity with all the data sources and can collect and store data.

C. **Low cost and high speed**: Companies in this category use data-rich machinery, and they must store the generated data to maintain the integrity of the audit trail. Over time, the cost to store and maintain data becomes very high, and the speed of storing and retrieval becomes slow. Cloud computing provides various tiers of storage and retrieval options.

D. **Quick troubleshooting:** Biopharmaceutical companies use various manufacturing and computerized equipment built and supplied by vendors. Even with timely maintenance, equipment can fail, and a subject matter expert or technician from the vendor needs to fly in and troubleshoot it [9]. Cloud computing allows companies to host applications and data in the cloud, enabling them to provide remote login to vendors and quickly troubleshoot issues. This feature saves both time and money for the Vendor and manufacturing company.

E. **Reduced Paperwork:** Documentation and records in the biopharmaceutical manufacturing industry are requirements for good manufacturing practice (GMP) regulations. Internal and external audits in these companies involve going through stacks of paper records, which can get messy [8]. Cloud computing offers online applications and databases to streamline the documents and manufacturing records, making it easy for process owners to troubleshoot any issue in manufacturing and for internal and external auditors to audit and provide licenses to operate.

F. **Minimum maintenance:** Cloud computing can also serve as a Software as a Service (SaaS) provider. Implementing a SaaS solution can take a few days/ weeks compared to implementing a solution in on-premises servers and databases. Cloud computing maintains the servers and databases and allows us to upscale or downscale depending on our computing needs, thus requiring minimal local IT support [7].

IV. LIMITATIONS OF CLOUD COMPUTING

A. **Auto updates:** Any IT system undergoes updates and upgrades, such as Security patches, Driver updates, Anti-virus updates, and OS upgrades. Cloud computing offers automatic updates and upgrades on servers, databases, and other systems. Companies in the biopharmaceutical industry are concerned about these changes and unsure if they will positively or negatively impact the business process or operations. The IT teams in these companies like to maintain redundancy to minimize the risks.

B. **Access to infrastructure:** The U.S. Food and Drug Administration (FDA) rules that computer systems and their controls should be available for FDA inspection [11]. Cloud computing makes the FDA inspection of computer systems and controls challenging, if not impossible. Failing to provide the required computer systems and controls will lead to issuing warning letters and withdrawing approvals.

C. **Impact on Performance:** Internet issues can directly impact Cloud computing performance by causing slow data transfer speeds, increased latency, and potential service disruptions. These performance issues can lead to network outages and data loss. Neither the cloud computing service provider nor the manufacturing facility will be

able to recover the lost data or overcome the network outage issue. This data loss due to performance issues may lead to record discrepancies and affect the product.

D. **Vendor Dependency:** Cloud computing service providers make it easy for companies to opt for their services. They provide easy solutions to migrate data and applications into their cloud platform and start utilizing the services at scale [10]. After migrating data and applications into a cloud solution, it can be challenging to migrate to a different one because of possible infrastructure incompatibility and dependency issues. Biopharmaceutical manufacturing companies prefer to be able to switch between cloud solutions when necessary.

E. **High implementation and integration costs:** Cloud computing services come with a high implementation cost due to the initial migration and storage of data. Cloud computing also requires manufacturing companies to utilize particular data or system integrators to transfer data from legacy systems to the cloud effectively. The cost of implementing integrators and transferring data is high and may not be cost-effective in the short term.

V. APPLICATIONS OF CLOUD COMPUTING IN BIOPHARMACEUTICAL MANUFACTURING

Cloud computing has numerous applications in biopharmaceutical manufacturing, driving efficiency, collaboration, and innovation. Below are some of the key applications that illustrate its value:

5.1 Real-Time Data Monitoring and Analytics: Cloud platforms enable real-time monitoring of manufacturing processes, allowing for continuous tracking of critical parameters such as temperature, humidity, pressure, and product quality. With cloud-based solutions, manufacturers can integrate IoT sensors into their equipment and machines, which send data to the cloud for analysis. Fig. 1 visualizes the data movement from IoT sensors into PLCs and SCADA. This data is monitored in real time using SCADA and HMI systems. The data from PLCs is also stored in the on-prem or cloud database for analytics and audit purposes[12, 13].
This data is monitored remotely and analyzed in real-time, leading to:

- Immediate corrective actions to prevent defects or downtime.
- Predictive analytics to anticipate potential process failures or deviations before they occur, reducing waste and improving operational efficiency.
- Automated alerts for process anomalies, ensuring compliance with quality control standards.

5.2 Process Automation and Control: Biopharmaceutical manufacturing involves complex processes that require precision and consistency. Cloud-based process automation applications

International Journal of Core Engineering & Management
Volume-7, Issue-10, 2024 ISSN No: 2348-9510

help improve productivity and ensure product quality[12, 13].
These include:

- Automated Manufacturing Execution Systems (MES): Cloud-based MES systems monitor and control the manufacturing process, integrating with other systems (e.g., ERP, LIMS) for seamless operation, as shown in Fig. 1. They provide real-time insights into batch performance, equipment status, and overall production efficiency.
- Robotic Process Automation (RPA): RPA powered by cloud solutions automates repetitive tasks, such as data entry, inventory updates, and reporting, improving efficiency and reducing human error.



Fig.1. Data Flow in Biopharmaceutical Manufacturing

5.3 Data Integration and Interoperability: Cloud computing allows for integrating disparate data sources within the biopharmaceutical manufacturing ecosystem[12, 13].
For example:

- Integration with Laboratory Information Management Systems (LIMS): Cloud platforms can integrate with LIMS to enable seamless data transfer between laboratory tests and

International Journal of Core Engineering & Management
Volume-7, Issue-10, 2024 ISSN No: 2348-9510

manufacturing processes. This feature ensures that the correct formulations and specifications are used in production.

- ERP System Integration: Cloud systems can be integrated with Enterprise Resource Planning (ERP) solutions to provide a holistic view of the production process, from procurement of raw materials to product distribution, as shown in Fig. 1. This enables better resource management and decision-making at both process and manufacturing plant level.

5.4 Data Storage, Management, and Security: Biopharmaceutical companies generate massive amounts of data throughout the manufacturing process. Cloud computing offers scalable data storage solutions that ensure the secure management of this data[12,13, 14].
Applications in this area include:

- Scalable Cloud Storage: Manufacturers can store vast amounts of data in the cloud without having to invest in physical storage infrastructure. Cloud platforms offer flexible storage options that can grow with the needs of the business. Fig. 1. shows scalable data storage options in SCADA, MES, and ERP layers.
- Data Backup and Recovery: Cloud environments provide automated data backup and disaster recovery solutions, ensuring that critical manufacturing data is protected and can be restored during a system failure.
- Data Security: Cloud providers offer robust security features, including encryption, multi-factor authentication, and access control, to protect sensitive biopharmaceutical data from cyber threats and unauthorized access.



Fig.2. Centralized Process/ Data Management in Biopharmaceutical Manufacturing

5.5 Supply Chain Optimization and Manufacturing Analytics: Cloud-based systems provide enhanced visibility into the biopharmaceutical supply chain, enabling manufacturers to track the entire journey of raw materials, intermediates, and finished products [15, 16].
Key applications in this domain include:

- Inventory Management: Cloud platforms enable real-time inventory level tracking,

reducing stockouts and overstocking risks. Automated reordering systems help ensure the right materials are always available.

- Demand Forecasting: Cloud platforms can help predict demand fluctuations by analyzing historical data and trends, enabling better planning and resource allocation.
- Predictive Maintenance: Cloud-based analytics platforms can predict equipment failures based on historical data and IoT sensor readings. This prediction helps manufacturers schedule maintenance before equipment breaks down, reducing downtime.
- Operational Optimization: By analyzing production data, cloud platforms can identify inefficiencies in the manufacturing process, enabling manufacturers to optimize throughput, reduce waste, and improve overall efficiency.

5.6 Collaboration Across Global Teams: Cloud environments provide a collaborative platform for biopharmaceutical teams across different geographical locations, as shown in Fig. 2. [12, 13, 14].

Key benefits include:

- Shared Data and Documents: Teams can access the same data and documents in real-time, ensuring everyone has the most up-to-date information.
- Cross-Functional Collaboration: Cloud-based project management tools allow scientists, engineers, and regulatory experts to collaborate seamlessly regardless of location.
- Virtual Meetings and Communication: Cloud-based communication tools such as video conferencing and instant messaging enable virtual meetings for discussions, updates, and troubleshooting.

5.7 Regulatory Compliance and Documentation Management: In the highly regulated biopharmaceutical industry, ensuring regulatory compliance is critical. Cloud-based solutions support manufacturers in adhering to industry standards such as Good Manufacturing Practices (GMP) and FDA regulations[15, 16].

Key applications include:

- Document Control: As shown in Fig. 2, cloud platforms provide a secure and centralized location for storing critical documents (e.g., batch records, quality assurance reports, regulatory submissions). Version control ensures that teams always work with the latest document revisions.
- Audit Trails: Cloud systems maintain automated audit trails that track every user action and modification in the system. These trails are essential for ensuring compliance and for regulatory body audits.
- Automated Reporting: Cloud platforms can automatically generate and submit regulatory reports, ensuring timely compliance with industry regulations and reducing human error.

VI. CONCLUSION

Cloud computing is a transformative technology for biopharmaceutical manufacturing, offering significant scalability, cost efficiency, and operational productivity advantages. Its ability to centralize data storage, improve connectivity across systems, streamline documentation, and enable real-time troubleshooting makes it an essential tool for modernizing the industry. By adopting cloud solutions, companies can better manage vast amounts of data, reduce production costs, and ensure compliance with stringent Good Manufacturing Practice (GMP) regulations.

Integrating cloud environments and biopharmaceutical manufacturing presents several challenges. Limitations such as the impact of automatic server updates, dependency on internet connectivity, vendor dependency, and regulatory compliance complexities pose significant hurdles. Moreover, we need to address the substantial upfront costs of migration and the challenges we face in preserving data integrity during system transitions.

For biopharmaceutical companies, the path forward lies in balancing these advantages and limitations through strategic planning and collaboration with cloud service providers. Based on the listed advantages and constraints, investing in a hybrid cloud computing model and robust data governance framework is essential. While implementing a cloud solution, ensuring alignment with regulatory standards by implementing risk mitigation strategies is essential. Similarly, cloud computing service providers should enhance their solutions to comply with specific industry protocols.

Ultimately, the success of cloud adoption in biopharmaceutical manufacturing will depend on its ability to drive innovation while maintaining the safety, quality, and efficacy of life-critical products. It requires a concerted effort from stakeholders across the industry to overcome barriers and fully harness cloud technology's transformative potential.

REFERENCES

1. L. Abboud and S. Hensley, “New Prescription for Drug Makers: Update the Plants,” WSJ, Sept. 3, 2003.
2. FDA, Guidance for Industry: PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, no. September, 2004.
3. U.S. Food and Drug Administration, Pharmaceutical CGMPs for the 21st Century—A Risk-Based Approach. FDA, 2004.
4. Agilent, Data Integrity: Principles of ALCOA+. Agilent, 2020. [Online]. Available: https://www.agilent.com/en/products/software-informatics/openlab-software-suite/alcoa-plus. [Accessed: Nov. 20, 2023].

5. FDA, Current Good Manufacturing Practice (CGMP) Regulations. U.S. Food and Drug Administration, 2020. [Online]. Available: https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations. [Accessed: Nov. 25, 2023].
6. M. May, "Forecast calls for clouds over biological computing," Nature Medicine, vol. 16, no. 1, p. 6, 2010. [Online]. Available:https://link.gale.com/apps/doc/A216681828/AONE?u=anon~c35a6465&sid=googleScholar&xid=dc4bd7ba. [Accessed: Nov. 21, 2023].
7. L. Bowers, "Cloud Computing Efficiency," Applied Clinical Trials, vol. 20, no. 7, 2011.
8. A. Shurell, "Life sciences joins the cloud," Pharma, vol. 6, no. 6, pp. 54, 56, 58, Nov./Dec. 2010. [Online]. Available: ProQuest Health and Medical Complete, Document ID: 2249071871. [Accessed: Nov. 8, 2023].
9. G. Vandeweyer, E. Reyniers, W. Wuyts, L. Rooms, and R. F. Kooy, "CNV-WebStore: Online CNV analysis, storage and interpretation," BMC Bioinformatics, vol. 12, no. 1, 2011. doi: 10.1186/1471-2105-12-4.
10. T. Sommer, "Cloud computing in emerging biotech and pharmaceutical companies," Communications of the IIMA, vol. 13, no. 3, p. 3, 2013.
11. FDA, Part 11, Electronic Records; Electronic Signatures - Scope and Application. U.S. Food and Drug Administration. [Online]. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application. [Accessed: Nov. 18, 2023].
12. L. Ren, L. Zhang, L. Wang, F. Tao, and X. Chai, "Cloud manufacturing: key characteristics and applications," International Journal of Computer Integrated Manufacturing, vol. 30, no. 6, pp. 501–515, 2014. doi: 10.1080/0951192X.2014.902105.
13. F. Tao, Y. Cheng, L. D. Xu, L. Zhang, and B. H. Li, "CCIoT-CMfg: Cloud computing and Internet of Things-based cloud manufacturing service system," IEEE Transactions on Industrial Informatics, vol. 10, no. 2, pp. 1435-1442, May 2014, doi: 10.1109/TII.2014.2306383.
14. P. Wang, R. X. Gao, and Z. Fan, "Cloud computing for cloud manufacturing: benefits and limitations," Journal of Manufacturing Science and Engineering, vol. 137, no. 4, p. 040901, 2015.
15. L. Wu and C. Yang, "A solution of manufacturing resources sharing in cloud computing environment," in Cooperative Design, Visualization, and Engineering, Y. Luo, Ed. Lecture Notes in Computer Science, vol. 6240, Berlin, Heidelberg: Springer, 2010. doi: 10.1007/978-3-642-16066-0_36.
16. H. Coullon and J. Noyé, "Reconsidering the relationship between cloud computing and cloud manufacturing," in Service Orientation in Holonic and Multi-Agent Manufacturing, T. Borangiu, D. Trentesaux, A. Thomas, and O. Cardin, Eds. Studies in Computational Intelligence, vol. 762, Cham: Springer, 2018. doi: 10.1007/978-3-319-73751-5_16.

International Journal of Core Engineering & Management
Volume-7, Issue-10, 2024 ISSN No: 2348-9510